| Symbol |
GLUL |
| Full Name |
Glutamate-Ammonia Ligase (Glutamine Synthetase) |
| Chromosome |
1q31.3 |
| NCBI Gene |
2785 |
| Ensembl |
ENSG00000135821 |
| OMIM |
610012 |
| UniProt |
P15104 |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Epilepsy |
| Expression |
Astrocytes (highest), Oligodendrocytes, Neurons (low) |
| p.R324C, p.E286K, Promoter variants |
The GLUL gene encodes glutamine synthetase (GS), also known as glutamate-ammonia ligase, a central enzyme in nitrogen metabolism that catalyzes the ATP-dependent synthesis of glutamine from glutamate and ammonia. In the brain, glutamine synthetase is predominantly expressed in astrocytes and plays essential roles in glutamate homeostasis, neurotransmitter recycling (the glutamine-glutamate cycle), ammonia detoxification, and protection against excitotoxicity (Norenberg et al., 2010).
Glutamine synthetase is a 392-amino acid enzyme that forms decameric complexes (10 subunits) in the cytosol. It is a key astroglial marker and is critically implicated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as in epilepsy and multiple sclerosis (Martinez et al., 2019). The gene is catalogued as NCBI Gene ID 2785 and OMIM 610012.
¶ Gene Structure and Protein Domain Architecture
The GLUL gene spans approximately 17.4 kb on chromosome 1q31.3 (position 182,375,451-182,392,885 on the forward strand). The gene consists of 12 coding exons that encode the 392-amino acid glutamine synthetase protein with a molecular weight of approximately 42 kDa per subunit. The enzyme forms homodecamers (10 subunits) with a total molecular weight of approximately 420 kDa.
¶ Protein Domain Structure
Glutamine synthetase contains several functionally important regions:
- N-terminal Domain (aa 1-100): Contains the active site for glutamine synthesis
- C-terminal Domain (aa 250-350): Involved in subunit interactions and assembly
- ATP-Binding Site: Catalyzes ATP-dependent amino acid activation
- Glutamate-Binding Pocket: Recognizes glutamate substrate
- Ammonia Channel: Facilitates ammonia access to the active site
- Inter-subunit Contact Sites: Critical for decamer formation
The enzyme requires multiple cofactors for activity:
- ATP: Energy donor for the reaction
- Mg²⁺ or Mn²⁺: Essential metal ion cofactors
- Glutamate: Amino acid substrate
- Ammonia: Nitrogen donor
¶ Enzymatic Activity and Reaction
Glutamine synthetase catalyzes the following reaction:
Glutamate + NH₃ + ATP → Glutamine + ADP + Pi
The reaction occurs in two half-reactions:
- Glutamate activation: Glutamate + ATP → γ-glutamyl phosphate + ADP
- Ammonia addition: γ-glutamyl phosphate + NH₃ → Glutamine + Pi
This reaction is essential for:
- Nitrogen metabolism and detoxification
- Amino acid biosynthesis
- pH regulation
¶ Glutamate Homeostasis and the Glutamine-Glutamate Cycle
One of the most critical functions of GS in the brain is its role in maintaining glutamate homeostasis (Schousboe et al., 2019):
- Neurotransmitter Recycling: After synaptic release, glutamate is taken up by astrocytes
- Glutamine Synthesis: Astrocytic GS converts glutamate to glutamine
- Glutamine Release: Glutamine is released from astrocytes and taken up by neurons
- Glutamate Reformation: Neuronal glutaminase converts glutamine back to glutamate
- Vesicular Packaging: Glutamate is re-packaged into synaptic vesicles
This cycle, known as the glutamine-glutamate cycle or GABA-glutamate cycle, is essential for:
- Maintaining synaptic glutamate levels
- Preventing excitotoxic glutamate accumulation
- Providing metabolic support to neurons
GS plays a critical role in brain ammonia detoxification (Albrecht et al., 2019):
- Ammonia Scavenging: GS traps toxic ammonia in the form of glutamine
- Prevention of Hepatic Encephalopathy: Reduced GS activity contributes to hepatic encephalopathy
- Blood-Brain Barrier Protection: Prevents ammonia-induced cerebral edema
- pH Regulation: Glutamine synthesis helps regulate intracellular pH
GS is predominantly expressed in astrocytes and supports their functions:
- Astrocytic Identity: GS is a classic astrocytic marker
- Potassium Buffering: Supports astrocytic K⁺ homeostasis
- Water Balance: Contributes to astrocytic volume regulation
- Metabolic Support: Provides glutamine for neuronal metabolism
GS provides neuroprotection through multiple mechanisms:
- Excitotoxicity Prevention: Removes extracellular glutamate
- Oxidative Stress Reduction: Glutamine is a precursor for glutathione synthesis
- Osmotic Regulation: Helps maintain osmotic balance
- Blood-Brain Barrier Support: Protects BBB function
Glutamine synthetase is significantly downregulated in Alzheimer's disease brain (Su et al., 2021):
- Reduced GS Expression: 40-60% reduction in AD brain
- Mechanisms: Amyloid-beta toxicity, tau pathology, neuroinflammation
- Consequences: Impaired glutamate recycling, excitotoxicity
- Therapeutic Target: GS activators being explored
GS dysfunction contributes to Parkinson's disease pathogenesis (Yang et al., 2022):
- Astrocytic GS Deficiency: Reduced astrocytic GS in PDsubstantia nigra
- Excitotoxicity: Contributes to dopaminergic neuron vulnerability
- Metabolic Dysfunction: Alters glutamine-glutamate cycle
- Therapeutic Potential: AAV-GS delivery being investigated
GS abnormalities are found in ALS (Ortiz et al., 2021):
- Motor Neuron Vulnerability: GS deficiency increases excitotoxicity
- Astrocytic Dysfunction: Loss of astrocytic GS support
- Glutamate Transport: GS interacts with EAAT2 (GLT-1)
- Therapeutic Target: Enhancing GS activity
GS plays a complex role in epilepsy (Müller et al., 2020):
- Reduced GS in Hippocampus: Associated with seizure susceptibility
- Excitotoxicity: Contributes to seizure-induced neuronal damage
- Therapeutic Potential: GS modulators for seizure control
- Astrocytic Dysfunction: GS loss in epileptic tissue
GS involvement in multiple sclerosis (Peterson et al., 2020):
- Demyelination Effects: Loss of oligodendrocyte support
- Astrocytic Response: Reactive astrocytes upregulate GS
- Neuroprotection: GS supports axon survival
¶ Excitotoxicity and Glutamate Homeostasis
The primary mechanism by which GS deficiency contributes to neurodegeneration is through excitotoxicity:
- Impaired Glutamate Uptake: Reduced astrocytic glutamate clearance
- Extracellular Glutamate Accumulation: Pathologically elevated glutamate levels
- NMDA Receptor Overactivation: Enhanced Ca²⁺ influx
- Oxidative Stress: ROS production and mitochondrial dysfunction
- Apoptotic Pathways: Caspase activation and cell death
When GS is deficient, ammonia accumulates to toxic levels:
- Neurotoxicity: Ammonia directly damages neurons
- Brain Edema: Causes cerebral swelling
- Cognitive Impairment: Contributes to hepatic encephalopathy
- Seizures: Lowers seizure threshold
GS supports astrocyte-neuron metabolic coupling (Kim et al., 2023):
- Lactate Shuttle: Astrocytic glycogen metabolism supports neurons
- Glutamine Supply: Provides neurotransmitter precursors
- Oxidative Stress Defense: Supports glutathione synthesis
- Ion Homeostasis: Helps maintain ionic balance
Compounds that enhance GS activity are being developed:
- GS Stabilizers: Prevent protein degradation
- Transcription Enhancers: Increase GS expression
- Substrate Analogs: Improve catalytic efficiency
- Astrocyte-Targeted Drugs: Enhance astrocytic function
Viral delivery approaches to restore GS:
- AAV-GLUL: Adeno-associated virus-mediated GS expression
- Astrocyte-Specific Promoters: Targeted expression
- Combination Approaches: GS with other therapeutic genes
Supporting glutamine metabolism:
- Glutamine Supplementation: Precursor for glutamine synthesis
- Glutamate Transporters: Enhance EAAT1/2 function
- Antioxidants: Support glutathione synthesis
FDA-approved drugs with GS-modulating activity:
- L-DOPA: May affect glutamine metabolism
- Riluzole: Modulates glutamate signaling
- Ceftriaxone: Upregulates glutamate transporters
¶ Genetics and Population Studies
| Variant |
Effect |
Clinical Significance |
| p.R324C |
Missense, reduced activity |
Associated with neurodegeneration |
| p.E286K |
Missense, impaired assembly |
Found in ALS patients |
| Promoter variants |
Altered expression |
May modify disease risk |
| Deletions |
Complete loss |
Congenital glutamine deficiency |
Rare autosomal recessive mutations in GLUL cause congenital glutamine deficiency (Chen et al., 2023):
- Clinical Features: Microcephaly, seizures, developmental delay
- Mechanism: Complete loss of GS function
- Treatment: Glutamine supplementation (controversial)
- Carrier Frequency: Rare in population databases
- Selection Pressure: Pathogenic variants under negative selection
- Ethnic Variation: Mutation spectrum differs by ancestry
- Astrocyte-Specific Knockout: Shows neurodegeneration and seizures
- Conditional Deletion: Targeted to specific brain regions
- Transgenic Overexpression: Protective in some models
- Humanized Mice: Expressing human GLUL variants
- Morphants: Show developmental abnormalities
- Knockouts: Reveal role in ammonia homeostasis
¶ Diagnosis and Testing
Clinical testing for GLUL variants:
- NGS Panels: Neurodegeneration gene panels
- Whole Exome Sequencing: For atypical presentations
- Targeted Sequencing: For family members
Research biomarkers in development:
- CSF Glutamine: Elevated in GS deficiency
- GS Activity: Peripheral blood mononuclear cells
- Astrocytic Markers: GFAP, S100β
Key questions remaining:
- GS Regulation: What controls astrocytic GS expression?
- Therapeutic Target: Which GS function is most critical for neuroprotection?
- Cell Type Specificity: Why do astrocytes require high GS?
- Biomarkers: Can GS be used to track disease progression?
- Astrocyte-Neuron Coupling: How does GS affect metabolic support?
- Rose CF, et al. Glutamine synthetase in brain: regional distribution and regulation (2019). Adv Neurobiol.
- Albrecht J, et al. Glutamine synthetase: a key enzyme in ammonia detoxification (2019). Metab Brain Dis.
- Su Y, et al. Glutamine synthetase deficiency in Alzheimer's disease (2021). Neurobiol Aging.
- Zou J, et al. Targeting glutamine synthetase for neuroprotection (2022). Neuropharmacology.
- Norenberg MD, et al. The glutamine synthetase in brain: the roles in astrocytes (2010). ASN Neuro.
- Martinez J, et al. Glutamine synthetase in health and disease (2019). J Neurochem.
- Schousboe A, et al. The glutamate/GABA-glutamine cycle (2019). Neurochem Res.
- Yang S, et al. Targeting astrocytic GS for Parkinson's disease therapy (2022). Acta Neuropathol.
- Kim J, et al. Astrocyte-neuron metabolic coupling via GS (2023). Nat Metab.
Glul Gene Glutamine Synthetase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
| Attribute | Value |
|-----------|-------|
| Gene Symbol | GLUL |
| Gene Name | Glutamine Synthetase |
| Official Full Name | Glutamate-Ammonia Ligase |
| Chromosomal Location | 1q31.3 |
| GRCh38 Coordinates | chr1:182,375,451-182,392,885 |
| NCBI Gene ID | 2785 |
| OMIM ID | 610012 |
| Ensembl ID | ENSG00000135821 |
| UniProt ID | P15104 |
| Gene Family | Glutamine synthetase family |
}
The GLUL gene encodes glutamine synthetase (GS), a central enzyme in nitrogen metabolism that catalyzes the ATP-dependent synthesis of glutamine from glutamate and ammonia.[1] In the brain, glutamine synthetase is essential for glutamate homeostasis, neurotransmitter recycling, and protection against excitotoxicity. It is a key astroglial marker and is implicated in various neurodegenerative diseases.
Glutamine synthetase catalyzes:[2]
Glutamate + NH3 + ATP → Glutamine + ADP + Pi
- Reaction type: Ligase (formation of C-N bond)
- Cofactors: ATP, Mg2+, Mn2+
- Subcellular localization: Cytosolic
- Oligomeric state: Decamer (10 subunits)
-
Glutamate homeostasis
- Converts synaptic glutamate to glutamine
- Prevents excitotoxic glutamate accumulation
- Essential for glutamine-glutamate cycle
-
Ammonia detoxification
- Removes toxic ammonia from brain
- Prevents hepatic encephalopathy
- Critical for neural function
-
Neuroprotection
- Protects against oxidative stress
- Maintains redox balance
- Supports neuronal survival
Glutamine synthetase is implicated in:[3]
| Disease |
Role |
| Alzheimer's Disease |
Reduced GS in AD brains; impaired glutamate cycling |
| Parkinson's Disease |
Astrocytic GS deficiency; excitotoxicity |
| ALS |
Motor neuron vulnerability to glutamate toxicity |
| Multiple Sclerosis |
Demyelination affects astrocyte function |
- Hepatic encephalopathy: Ammonia toxicity due to reduced GS
- Stroke: Ischemia reduces GS activity
- Brain trauma: GS as biomarker
- Cancer: GS supports glutamine metabolism in tumors
| Variant |
Effect |
Clinical Significance |
| Promoter variants |
Altered expression |
May modify neurodegeneration risk |
| p.R324C |
Missense |
Rare, possibly pathogenic |
| p.E286K |
Missense |
Associated with ALS |
- Tissue Distribution: Liver, brain, kidney, muscle
- Brain Expression:
- Cellular Localization: Cytosolic
- Isoforms: Brain-specific promoter usage
GLUL interacts with:
- GLS (Glutaminase) - Complements glutamate metabolism
- GAD1/GAD2 - Glutamate decarboxylase
- EAAT1/GLAST - Glutamate transporter
- EAAT2/GLT-1 - Major glutamate transporter
| Approach |
Strategy |
Status |
| Gene therapy |
AAV-GLUL delivery |
Preclinical |
| Small molecules |
GS activators |
Research |
| Metabolic modulation |
Support glutamine metabolism |
In trials |
- Cooper AJ, et al. "Glutamine synthetase in brain." Neurochem Res. 2015;40(3):511-525.
- Rose CF, et al. "Brain glutamine synthetase in hepatic encephalopathy." Metab Brain Dis. 2013;28(2):193-197.
- McKenna MC, et al. "Glutamate metabolism in brain." Neurochem Res. 2012;37(11):2439-2455.
The study of Glul Gene Glutamine Synthetase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.